Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 21 -30 of 285 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 11/17/2006 First Published: 1/23/2004


21.		Phase III Randomized Study of Fluorouracil and Leucovorin Calcium With Irinotecan or Oxaliplatin and With or Without Cetuximab in Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				CALGB-80203 CALGB-80203, NCT00077233


22.		Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				CA225006 NCT00063141

Last Modified: 12/18/2006 First Published: 8/24/2004


23.		Phase III Randomized Study of Adjuvant Chemotherapy Comprising Fluorouracil and Irinotecan With or Without Leucovorin Calcium Versus No Adjuvant Therapy in Patients With Resected Stage II Adenocarcinoma of the Colon

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 75				Other				FFCD-EORTC-40012 EORTC-40012, PETACC-4, NCT00091312


24.		PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				20040249 NCT00115765


25.		Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 75				Pharmaceutical / Industry				CPT-GMA-301 A5961076, NCT00143403


26.		Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 75				Pharmaceutical / Industry				XRP4174D-3001 NCT00143455


27.		Irinotecan Versus Only Best Supportive Care for Gastric Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 to 75				Other				irinotecan vs. bsc NCT00144378


28.		A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				20 to 70				Other				JCOG0202-MF C000000095, NCT00144989


29.		A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				20 to 75				Other				JCOG9912 C000000062, NCT00142350


30.		Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Other				SCRI UNKPRI 12 IRUSIRES0215, CPTAIV-0020-417, B9E-US-X423, NCT00193596

Select All on One Page


					< Previous 1 2 3 4 5 6 Next >

| | | | | | | |

A Service of the National Cancer Institute